€36.75
0.68% today
Xetra, Apr 02, 05:35 pm CET
ISIN
DE000A2GS5D8
Symbol
DMP
Index
Sector
Industry

Dermapharm Stock price

€36.75
-3.05 7.66% 1M
+2.85 8.41% 6M
-2.15 5.53% YTD
+4.90 15.38% 1Y
-23.00 38.49% 3Y
+0.76 2.11% 5Y
+10.75 41.35% 10Y
Xetra, Closing price Wed, Apr 02 2025
+0.25 0.68%
ISIN
DE000A2GS5D8
Symbol
DMP
Index
Sector
Industry

Key metrics

Market capitalization €1.97b
Enterprise Value €2.83b
P/E (TTM) P/E ratio 17.27
EV/FCF (TTM) EV/FCF 24.80
EV/Sales (TTM) EV/Sales 2.39
P/S ratio (TTM) P/S ratio 1.66
P/B ratio (TTM) P/B ratio 3.25
Dividend yield 2.47%
Last dividend (FY24) €0.90
Revenue growth (TTM) Revenue growth 4.00%
Revenue (TTM) Revenue €1.18b
EBIT (operating result TTM) EBIT €218.83m
Free Cash Flow (TTM) Free Cash Flow €114.02m
Cash position €121.31m
EPS (TTM) EPS €2.11
P/E forward 15.43
P/S forward 1.59
EV/Sales forward 2.29
Show more

Is Dermapharm a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Dermapharm Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Dermapharm forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Dermapharm forecast:

Buy
100%

Financial data from Dermapharm

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1,181 1,181
4% 4%
100%
- Direct Costs 784 784
0% 0%
66%
397 397
13% 13%
34%
- Selling and Administrative Expenses 87 87
167% 167%
7%
- Research and Development Expense - -
-
-
309 309
3% 3%
26%
- Depreciation and Amortization 91 91
13% 13%
8%
EBIT (Operating Income) EBIT 219 219
3% 3%
19%
Net Profit 114 114
82% 82%
10%

In millions EUR.

Don't miss a Thing! We will send you all news about Dermapharm directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dermapharm Stock News

AD HOC NEWS
6 days ago
Dermapharm Holding SE / DE000A2GS5D8
AD HOC NEWS
6 days ago
Dermapharm Holding SE / DE000A2GS5D8
AD HOC NEWS
20 days ago
Der Arzneimittelhersteller Dermapharm DE000A2GS5D8 hat im vergangenen Jahr im Tagesgeschäft ein Stück zugelegt.
More Dermapharm News

Company Profile

Dermapharm Holding SE engages in the development, manufacture. and market of patent-free pharmaceutical products. The company also involves in in-house development, in-house production, and distribution of pharmaceuticals and other healthcare products. It offers its products through the following brands: Dekristol 20,000 I.E., bite away, Herpotherm, sikapur, Ampho-Moronal, Solacutan, Ciclocutan, Minoxicutan, Prednisolut, Dienovel, Lactofem, Finapil, Panthenol-Augensalbe JENAPHARM, and Suxilep. The company was founded in 1991 and is headquartered in Grunwald, Germany.

Head office Germany
CEO Hans-Georg Feldmeier
Employees 3,600
Founded 1991
Website www.dermapharm.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today